EUCTR2008-003917-29-GB进行中（未招募）不适用
A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents
Gilead Sciences Incorporated0 个研究点目标入组 24 人开始时间: 2008年10月17日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:
- •12 years to < 18 years of age (consent of parent or guardian required per local state or country law)
- •Subjects able to give written assent prior to any screening evaluations and willing to comply with study requirements
- •Parent or guardian able to give written informed consent prior to any screening
- •evaluations and willing to comply with study requirements
- •Body Surface Area (BSA) = 1.2 m2
- •Weight = 40 kg (88 lbs)
- •Able to swallow oral tablets
- •HIV-1 RNA >1,000 copies/mL OR < 400 copies/mL at screening
- •Six months of antiretroviral treatment experience or at least one documented resistance mutation as defined by current IAS-USA Guidelines.These resistant gene mutations must be documented in a historical genotype report(s), or in the genotype/phenotype report at screening provided by Gilead Sciences.
- •Subjects must have been on a stable antiretroviral regimen (or be off antiretroviral
- •therapy completely) for at least 30 days prior to the Screening visit. Subjects undergoing dose modifications to their antiretroviral regimen for growth, or switching medication formulations are considered to be on a stable antiretroviral regimen.
- •Subjects must be able to receive at least two fully-active antiretroviral agents one of which one must be a fully-active ritonavir-boosted protease inhibitor (PI/r) (fully-active is defined by phenotypic analysis as being below the lower clinical or biological cutoff for each drug). (NOTE: This inclusion criteria is not applicable for subjects with
- •screening HIV-1 RNA < 400 copies/mL)
- •Normal ECG (or if abnormal, determined by investigator to be not clinically significant)
- •Adequate renal function:
- •Estimated glomerular filtration rate = 60 mL/min/1.73m2
- •Estimated Glomerular Filtration Rate (GFR) using Schwartz Formula
- •(mL/min/1.73m2) = k × L/Scr
- •[(k is a proportionality constant: for adolescent females = 12 years old is 0.55; and for adolescent males = 12 years old is 0.70); L is height in centimeters (cm); and Scr is serum creatinine (mg/dL)]
- •Hepatic transaminases (AST and ALT) = 2.5 × upper limit of normal (ULN)
- •Total bilirubin = 1.5 mg/dL, or normal direct bilirubin (subjects with documented
- •Gilbert’s Syndrome or hyperbilirubinemia due to indinavir or atazanavir therapy may
- •have total bilirubin up to 5 × ULN)
- •Adequate hematologic function (absolute neutrophil count = 1,000/mm3; platelets
- •= 25,000/mm3; hemoglobin = 8.0 g/dL)
- •Prothrombin time = 1.25 × ULN
- •Serum lipase = 1.5 × ULN
- •Negative serum pregnancy test (females)
- •Females (of childbearing potential i.e., not surgically sterile) must agree to utilize
- •effective contraception methods [two separate forms of contraception, one of which must be an effective barrier method, or be non-heterosexually active, practice sexual
- •abstinence or have a vasectomized partner (confirmed sterile)] while on study treatment and for 30 days following the last dose of study drugs
- •Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
- •Male subjects who are sexually active must be willing to use effective barrier
- •contraception (e.g., condom with spermicide) during heterosexual intercourse from
- •screening through completion of the study and continue for at least 30 days from date of last dose of study drug
- •Life expectancy = 1 year
排除标准
- •Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
- •A new AIDS-defining condition diagnosed within the 30 days prior to screening (Refer to Appendix 6 of the protocol).
- •Prior treatment with any HIV-1 integrase inhibitor
- •Females who are breastfeeding
- •Subjects receiving ongoing therapy with any medication that is not to be taken with a component of the BR, including drugs not to be taken with ritonavir (refer to prescribing information)
- •Administration of any of the medications mentioned in the protocol must be discontinued at least 30 days prior to the Baseline visit/Day 1 and for the duration of the study.
- •Current alcohol or substance use judged by the investigator to potentially interfere with subject study compliance
- •Active malignancy or treatment for active malignancy other than cutaneous Kaposi’s
- •sarcoma (KS) or basal cell carcinoma in the last two years. Subjects with biopsyconfirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of baseline and are not anticipated to require systemic therapy during the study
- •Active, serious infections (other than HIV-1 infection) requiring parenteral (other than oral) antibiotic or anti-fungal therapy within 30 days prior to baseline, unless agreed upon by the GSI Medical Monitor
- •Participation in any other clinical treatment trial without prior approval from the Sponsor is prohibited while participating in this trial
- •Any other clinical condition or prior therapy that, in the opinion of the investigator,
- •would make the subject unsuitable for the study or unable to comply with the dosing
- •requirements
研究者
相似试验
已完成
1 期
A Phase 1 Study of the Pharmacokinetics and Safety of IRX211 in Healthy VolunteersNeurological - Other neurological disordersComplex Regional Pain SyndromeACTRN12623000465651InhaleRx Ltd28
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660:cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-ITASTEX PHARMACEUTICALS230
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660: cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-GBAstex Pharmaceuticals, Inc.230
招募中
2 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.2024-516679-33-00Taiho Oncology Inc.16
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660: cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-HUAstex Pharmaceuticals, Inc.230